Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central nervous process, conolidine modulates alternate molecular targets. A Science Innovations review found that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://jimio012sfr8.blogunok.com/profile